Can improving longevity literacy motivate interest in life annuities?
How to cite
Lou, Hanlin; Bateman, Hazel; Hanewald, Katja; Yan, Jiamin. 2025. "Can improving longevity literacy motivate interest in life annuities?." AEA RCT Registry. AEARCTR-0015936. https://doi.org/10.1257/rct.15936-1.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
This study aims to investigate the role of longevity literacy in the interest in lifetime annuities through an online experimental survey. We introduce a lifetime income product to Australians who are near retirement and currently have, or previously have had, an account with a superannuation fund, and elicit their interest in using the product. We apply a between-subjects design to examine how different types of longevity literacy interventions affect participants’ interest in the product. We design seven treatment interventions, including eliciting longevity beliefs (life expectancy and survival probabilities), and providing either objective or personalized information about life expectancy, survival probabilities, and potential financial consequences. Participants are randomly assigned to one control group or one of sixteen treatment groups. Those in the treatment groups receive one or more of the interventions. By comparing levels of interest across experimental groups, we can assess the individual and interaction effects of these interventions on participants’ interest in lifetime annuities.
Intervention
Treatment 1: Longevity Elicitation (life expectancy)
Participants are asked about their expected life expectancy.
Treatment 2: Longevity Elicitation (survival probabilities)
Participants are asked about the probability that they will live to ages 85, 90, and 95.
Treatment 3: Financial Consequence Information
Participants are informed about potential financial challenges during retirement. An example is presented showing how a retiree could run out of their superannuation.
Treatment 4: Objective Life Expectancy Information
Participants are informed of the average life expectancy of people of the same age and gender as themselves.
Treatment 5: Objective Survival Probabilities Information
Participants are shown the probabilities of people of the same age and gender will live to ages 85, 90, and 95.
Treatment 6: Personalized Life Expectancy Information
Participants are given an estimate of their own life expectancy, calculated based on their demographics, health conditions, and lifestyle.
Treatment 7: Personalized Survival Probabilities Information
Participants are presented with the probabilities that they will live to ages 85, 90, and 95, based on their personal demographics, health conditions, and lifestyle.
Experimental design
We will conduct an online experiment in Australia using the survey platform Pureprofile. To be eligible for participation, individuals must be aged 50–75, reside in Australia, and currently have or previously have had an account with a superannuation fund. Participants will receive approximately 8 Australian dollars for completing the survey.
Participants will first be screened to form a sample representative of the Australian population aged 50-75 in terms of gender and wealth distribution. We will then collect basic health and lifestyle information that may influence life expectancy. After that, participants will be randomly assigned to one of 17 experimental groups.
In the Control Group, participants are introduced to a lifetime income product and asked about their interest in using it. In contrast to the Control Group, participants assigned to the treatment groups will receive one or more treatments before the lifetime income product is introduced.
The treatments are assigned as follows:
Treatment Group 1: Participants are asked about their life expectancy (Treatment 1).
Treatment Group 2: Participants are asked about the probability they will live to ages 85, 90, and 95 (subjective survival probabilities) (Treatment 2).
Treatment Group 3: Participants are asked both their life expectancy (Treatment 1) and their subjective survival probabilities (Treatment 2).
Treatment Group 4: Participants are presented with financial consequence information (Treatment 3).
Treatment Group 5: Participants are asked about their life expectancy (Treatment 1) and then receive objective life expectancy information based on people of the same age and gender (Treatment 4).
Treatment Group 6: Same as Treatment Group 5, with the addition of financial consequence information (Treatments 1, 3, and 4).
Treatment Group 7: Participants are asked about their life expectancy (Treatment 1) and then receive personalized life expectancy information based on their demographics, health status, and lifestyle (Treatment 6).
Treatment Group 8: Same as Treatment Group 7, with the addition of financial consequence information (Treatments 1, 3, and 6).
Treatment Group 9: Participants are asked about survival probabilities (Treatment 2) and then receive objective survival probabilities based on people of the same age and gender (Treatment 5).
Treatment Group 10: Same as Treatment Group 9, with the addition of financial consequence information (Treatments 2, 3, and 5).
Treatment Group 11: Participants are asked about survival probabilities (Treatment 2) and then receive personalized survival probabilities based on their demographics and health status and lifestyle (Treatment 7).
Treatment Group 12: Same as Treatment Group 11, with the addition of financial consequence information (Treatments 2, 3, and 7).
Treatment Group 13: Participants are asked both life expectancy and survival probabilities (Treatments 1 and 2) and then receive objective life expectancy and survival probability information (Treatments 4 and 5).
Treatment Group 14: Same as Treatment Group 13, with the addition of financial consequence information (Treatments 1, 2, 3, 4, and 5).
Treatment Group 15: Participants are asked both life expectancy and survival probabilities (Treatments 1 and 2) and then receive personalized life expectancy and survival probability information (Treatments 6 and 7).
Treatment Group 16: Same as Treatment Group 15, with the addition of financial consequence information (Treatments 1, 2, 3, 6, and 7).
We will also collect participants’ demographic characteristics, preferences, and other relevant information at the end of the survey.
Design details
Cited by
No citation data available for this registration yet.